Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00565461 · ClinicalTrials.gov registry record · Phase 2
LT Vaccine Patch Self-Administration Study
A Phase 2 study, sponsored by Intercell USA.
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
NCT00565461 is a Phase 2 study that has completed, run by Intercell USA. The registered enrollment target is 160 participants.
The verdict
NCT00565461, a Phase 2 study, has completed, sponsored by Intercell USA.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
Study Summary
To evaluate the immune responses achieved following self-administered heat-labile enterotoxin of E. coli (LT) vaccination by transcutaneous immunization compared to the immune responses achieved by clinician-administered vaccination.
Interventions
- BIOLOGICAL heat-labile enterotoxin of E. coli (LT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2007-11 |
| Est. Completion | 2008-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00565461
The ClinicalTrials.gov registry entry for NCT00565461 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intercell USA, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which heat-labile enterotoxin of E. coli (LT) is the first listed.
NCT00565461 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00565461 about?
NCT00565461 is a clinical study titled "LT Vaccine Patch Self-Administration Study". To evaluate the immune responses achieved following self-administered heat-labile enterotoxin of E. coli (LT) vaccination by transcutaneous immunization compared to the immune responses achieved by clinician-administered vaccination.
What is the current status of trial NCT00565461?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2007-11. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00565461?
The interventions under investigation include: heat-labile enterotoxin of E. coli (LT) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00565461?
This trial is sponsored by Intercell USA, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.